<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535522</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-285_101</org_study_id>
    <nct_id>NCT00535522</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer</brief_title>
  <official_title>A Multicenter, Open-Label, Noncomparative Phase I Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in&#xD;
      patients with advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile, including dose-limiting toxicities, maximum tolerated dose, recommended Phase II dose; and the pharmacokinetic profile.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective disease response by modified Response Evaluation Criteria in Solid Tumors.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>TAK-285</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-285 Dose Escalation Cohorts</intervention_name>
    <description>TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).</description>
    <arm_group_label>TAK-285</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-285 Recommended Phase 2 Dosing Cohort</intervention_name>
    <description>Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.</description>
    <arm_group_label>TAK-285</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  The subject has a histologically confirmed advanced non-hematologic malignancy.&#xD;
&#xD;
          -  The subject has a chemotherapy-free interval of at least 4 weeks prior to first dose&#xD;
             of study drug.&#xD;
&#xD;
          -  The subject is intolerant of, is not a candidate for, or the subject's disease is&#xD;
             refractory to established therapy known to provide clinical benefit for their disease.&#xD;
&#xD;
          -  A female subject of childbearing potential who is sexually active agrees to use&#xD;
             adequate contraception from Screening throughout the duration of the study, and for 30&#xD;
             days after the last dose of study drug. Male subjects should agree to use&#xD;
             contraception for the duration of the study, and for 30 days after the last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  The subject has a life expectancy of greater than 12 weeks.&#xD;
&#xD;
          -  The subject has an Eastern Cooperative Oncology Group performance status of 0 to 2.&#xD;
&#xD;
          -  The subject has the ability to swallow and retain oral medication&#xD;
&#xD;
          -  The subject's most recent test values within 2 weeks before the date of entry meet the&#xD;
             following standards:&#xD;
&#xD;
               -  Bone marrow function:&#xD;
&#xD;
                    -  Absolute neutrophil count ≥1500/mm3&#xD;
&#xD;
                    -  Hemoglobin ≥9.0g/dL, platelet count ≥100,000/mm3.&#xD;
&#xD;
               -  Liver function:&#xD;
&#xD;
                    -  Total bilirubin ≤1.5 times the upper limit of the standard value of each&#xD;
                       institution&#xD;
&#xD;
                    -  Aspartate aminotransferase and alanine aminotransferase ≤2.5 times the upper&#xD;
                       limit of the standard value of each institution.&#xD;
&#xD;
               -  Renal function:&#xD;
&#xD;
                    -  Serum creatinine ≤1.5 times the upper limit of the standard value of each&#xD;
                       institution.&#xD;
&#xD;
          -  In the recommended phase 2 dose Cohort, the subject has an accessible tumor for biopsy&#xD;
             and is willing to undergo 2 tumor biopsies.&#xD;
&#xD;
          -  In the recommended phase 2 dose Cohort, the subject has at least 1 measurable lesion&#xD;
             based on the treatment assessment standards for solid tumors.&#xD;
&#xD;
          -  In the recommended phase 2 dose Cohort, the subject has a tumor that expresses EGFR&#xD;
             and/or overexpresses erbB2.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  The subject has a symptomatic brain metastasis.&#xD;
&#xD;
          -  The subject has an uncontrollable pleural effusion, ascitic fluid, or pericardial&#xD;
             effusion.&#xD;
&#xD;
          -  The subject has active gastrointestinal bleeding as evidenced by either hematemesis or&#xD;
             melena.&#xD;
&#xD;
          -  The subject has acute gastrointestinal ulcers.&#xD;
&#xD;
          -  The subject has been treated with a small molecule inhibitor of EGFR or HER2 (except&#xD;
             for lapatinib).&#xD;
&#xD;
          -  The subject has a history of any cancer other than the present condition (except&#xD;
             nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete&#xD;
             remission and off all therapy for that disease for a minimum of 3 years.&#xD;
&#xD;
          -  The subject has significant cardiovascular impairment (history of New York Heart&#xD;
             Association class III or IV) or a history of myocardial infarction or unstable angina&#xD;
             within the past 6 months prior to study drug treatment.&#xD;
&#xD;
          -  The subject has a severe disease (other than cancer) that will likely affect the&#xD;
             prospects of survival or a history that will make it difficult to appropriately manage&#xD;
             and follow his or her progress in accordance with the protocol (serious organ&#xD;
             disorder, mental illness, drug abuse, alcohol dependency, etc.).&#xD;
&#xD;
          -  The subject requires prohibited treatment (drug, surgery or radiotherapy for treatment&#xD;
             of malignant tumor, drugs that could interact with TAK-285) except for radiotherapy of&#xD;
             limited area (&lt;20% of total bone marrow) in order to relieve the symptoms from&#xD;
             symptomatic bone metastasis.&#xD;
&#xD;
          -  The subject who has been treated with a drug, which inhibits or induces Cytochrome&#xD;
             P450 3A4 within 1 week prior to the start of treatment with the investigational drug.&#xD;
&#xD;
          -  The subject is pregnant or breast feeding.&#xD;
&#xD;
          -  The subject has participated in another clinical study/postmarketing clinical study&#xD;
             within 4 weeks prior to the start of treatment with TAK-285.&#xD;
&#xD;
          -  The subject is currently taking excluded medications, including:&#xD;
&#xD;
               -  Concurrent anticancer therapy with agents other than TAK-285.&#xD;
&#xD;
               -  The following prohibited medications and substances should not be used for at&#xD;
                  least 7 days prior to the start of the study and throughout completion:&#xD;
&#xD;
                    -  Strong CYP3A4 inhibitors&#xD;
&#xD;
                         -  Amiodarone&#xD;
&#xD;
                         -  Diltiazem&#xD;
&#xD;
                         -  Verapamil&#xD;
&#xD;
                         -  Human immunodeficiency virus protease inhibitors&#xD;
&#xD;
                         -  itraconazole&#xD;
&#xD;
                         -  ketoconazole&#xD;
&#xD;
                         -  macrolide antibiotics (excluding azithromycin)&#xD;
&#xD;
                    -  Strong CYP3A4 inducers&#xD;
&#xD;
                         -  Carbamazepine&#xD;
&#xD;
                         -  Efavirenz&#xD;
&#xD;
                         -  Nevirapine&#xD;
&#xD;
                         -  Phenytoin&#xD;
&#xD;
                         -  Rifabutin&#xD;
&#xD;
                         -  Rifampin.&#xD;
&#xD;
                         -  St. John's wort&#xD;
&#xD;
                    -  Medications and devices containing hormones such as oral contraceptives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenbaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>September 21, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>maximal tolerated dose</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

